271 related articles for article (PubMed ID: 26039708)
21. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract][Full Text] [Related]
22. Relationship of PI3K-Akt/mTOR/AMPK signaling pathway genetic mutation with efficacy and prognosis in nasopharyngeal carcinoma.
Chen Y; He Q; Ma H; Zhang L; Liu F; Han Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):165-173. PubMed ID: 35545406
[TBL] [Abstract][Full Text] [Related]
23. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
Slomovitz BM; Coleman RL
Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
[TBL] [Abstract][Full Text] [Related]
24. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
Sun CH; Chang YH; Pan CC
Histopathology; 2011 Jun; 58(7):1054-63. PubMed ID: 21707707
[TBL] [Abstract][Full Text] [Related]
25. Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer.
Kwan EM; Dai C; Fettke H; Hauser C; Docanto MM; Bukczynska P; Ng N; Foroughi S; Graham LK; Mahon K; Tan W; Wang X; Zhao Z; Zheng T; Zhou K; Yu J; Du P; Horvath LG; Jia S; Kohli M; Azad AA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250422
[TBL] [Abstract][Full Text] [Related]
26. Single-cell RNA sequencing reveals the mechanism of PI3K/AKT/mTOR signaling pathway activation in lung adenocarcinoma by KRAS mutation.
Xu L; Ding R; Song S; Liu J; Li J; Ju X; Ju B
J Gene Med; 2024 Jan; 26(1):e3658. PubMed ID: 38282149
[TBL] [Abstract][Full Text] [Related]
27. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.
Hou MM; Liu X; Wheler J; Naing A; Hong D; Coleman RL; Tsimberidou A; Janku F; Zinner R; Lu K; Kurzrock R; Fu S
Oncotarget; 2014 Nov; 5(22):11168-79. PubMed ID: 25426553
[TBL] [Abstract][Full Text] [Related]
28. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
Mackay HJ; Eisenhauer EA; Kamel-Reid S; Tsao M; Clarke B; Karakasis K; Werner HM; Trovik J; Akslen LA; Salvesen HB; Tu D; Oza AM
Cancer; 2014 Feb; 120(4):603-10. PubMed ID: 24166148
[TBL] [Abstract][Full Text] [Related]
29. Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.
Kong Y; Si L; Li Y; Wu X; Xu X; Dai J; Tang H; Ma M; Chi Z; Sheng X; Cui C; Guo J
Clin Cancer Res; 2016 Feb; 22(4):1018-27. PubMed ID: 26490311
[TBL] [Abstract][Full Text] [Related]
30. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.
Janku F; Kaseb AO; Tsimberidou AM; Wolff RA; Kurzrock R
Oncotarget; 2014 May; 5(10):3012-22. PubMed ID: 24931142
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma.
Seront E; Rottey S; Filleul B; Glorieux P; Goeminne JC; Verschaeve V; Vandenbulcke JM; Sautois B; Boegner P; Gillain A; van Maanen A; Machiels JP
BJU Int; 2016 Sep; 118(3):408-15. PubMed ID: 26779597
[TBL] [Abstract][Full Text] [Related]
32. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S
Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782
[TBL] [Abstract][Full Text] [Related]
33. Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma.
Shigeta K; Hasegawa M; Kikuchi E; Yasumizu Y; Kosaka T; Mizuno R; Mikami S; Miyajima A; Kufe D; Oya M
Cancer Sci; 2020 Oct; 111(10):3639-3652. PubMed ID: 32677159
[TBL] [Abstract][Full Text] [Related]
34. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
Pu X; Hildebrandt MA; Lu C; Lin J; Stewart DJ; Ye Y; Gu J; Spitz MR; Wu X
Lung Cancer; 2011 Jan; 71(1):82-8. PubMed ID: 20447721
[TBL] [Abstract][Full Text] [Related]
35. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
36. Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer.
Adamson AW; Ding YC; Steele L; Leong LA; Morgan R; Wakabayashi MT; Han ES; Dellinger TH; Lin PS; Hakim AA; Wilczynski S; Warden CD; Tao S; Bedell V; Cristea MC; Neuhausen SL
J Ovarian Res; 2023 Jul; 16(1):141. PubMed ID: 37460928
[TBL] [Abstract][Full Text] [Related]
37. Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer.
Ekstrand AI; Jönsson M; Lindblom A; Borg A; Nilbert M
Fam Cancer; 2010 Jun; 9(2):125-9. PubMed ID: 19731079
[TBL] [Abstract][Full Text] [Related]
38. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma.
Setsu N; Kohashi K; Fushimi F; Endo M; Yamamoto H; Takahashi Y; Yamada Y; Ishii T; Yokoyama K; Iwamoto Y; Oda Y
Cancer; 2013 Oct; 119(19):3504-13. PubMed ID: 23861137
[TBL] [Abstract][Full Text] [Related]
40. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
Wang LE; Ma H; Hale KS; Yin M; Meyer LA; Liu H; Li J; Lu KH; Hennessy BT; Li X; Spitz MR; Wei Q; Mills GB
J Cancer Res Clin Oncol; 2012 Mar; 138(3):377-85. PubMed ID: 22146979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
